Recognizing treatment resistance early can raise the response rate from 30% to 80% in difficult-to-treat cases. in this video, Jonathan Meyer, MD, shares his top strategies to manage it with Chris Aiken, MD.
Harnessing this drug interaction can reduce clozapine's metabolic risks, but it needs to be done with care.
Across all mental illnesses, especially in schizophrenia, the goal is to optimize cognitive functioning. Digital Psychiatry Section Editor John Torous, MD, MDI, sheds light on new advances.
Research uncovers the mechanism underlying the development of psychotic symptoms in schizophrenia and bipolar disorder. More in this video with Viviane Labrie, PhD, lead author of a recent study.
In this video segment, Dr. Peter Buckley addresses 2 questions:
• What factors do you consider when you offer depot medications to a patient with schizophrenia?
• What can be done to encourage the use of depot medications?
In recent years, violence has unfortunately become the tragic touchstone that too often draws the public’s attention to mental illness.